We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Stoke Therapeutics
2 own
3 watching
Current Price
$9.98
$0.72
(7.78%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
393.48M
52-Week High
26.6
52-Week Low
6.88
Average Volume
0.64M
Dividend Yield
--
P/E Ratio
--
Market Capitalization393.48M52-Week High26.652-Week Low6.88Average Volume0.64MDividend Yield--P/E Ratio--What does the Stoke Therapeutics do?
Stoke Therapeutics, Inc. are pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. They are developing novel antisense oligonucleotide, or ASO, medicines that target ribonucleic acid, or RNA, and modulate precursor-messenger RNA, or pre-mRNA, splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. They utilize their proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, to design ASOs to upregulate the expression of protein by individual genes in a patient. Their approach is designed to allow them to deliver in a highly precise, durable and controlled manner disease-modifying therapies to a broad range of relevant tissues, including the central nervous system, or CNS, eye, kidney and liver. They designed their lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. With a well-defined patient population based on routine genetic testing and learnings from recently approved drugs for the treatment of Dravet syndrome to inform the clinical and regulatory pathways for STK-001, they anticipate an efficient clinical program for STK-001. They plan to submit an investigational new drug application, or IND, for STK-001 by early 2020 and expect to initiate a Phase 1/2 clinical trial in the first half of 2020. They intend to nominate a second candidate to treat an additional genetic disease for preclinical development by the first half of 2020. Stoke Therapeutics, Inc. were incorporated under the laws of the State of Delaware in June 2014 under the name ASOthera Pharmaceuticals, Inc. They subsequently changed their name to Stoke Therapeutics, Inc. on May 18, 2016. Their principal executive office is
located at 45 Wiggins Avenue, Bedford, Massachusetts, 01730.
Read More
How much money does Stoke Therapeutics make?
News & Events about Stoke Therapeutics.
Business Wire
30days ago
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday...
Ticker Report
1month ago
Stoke Therapeutics (NASDAQ:STOK Get Rating) had its price objective reduced by research analysts at HC Wainwright from $70.00 to $35.00 in a note issued to investors on Monday, The Fly reports. The firm presently has a buy rating on the stock. HC Wainwrights price target...
Business Wire
2 months ago
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the...
PR Newswire
3 months ago
Moore Kuehn, PLLC Encourages Investors of Stoke Therapeutics, Inc. to Contact Law Firm Moore Kuehn, PLLC Encourages Investors of Stoke Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Oct. 18, 2022 NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located...
Frequently Asked Questions
Frequently Asked Questions
What is Stoke Therapeutics share price today?
Can Indians buy Stoke Therapeutics shares?
How can I buy Stoke Therapeutics shares from India?
Can Fractional shares of Stoke Therapeutics be purchased?
What are the documents required to start investing in Stoke Therapeutics stocks?
What is today’s traded volume of Stoke Therapeutics?
What is today’s market capitalisation of Stoke Therapeutics?
What is the 52-Week High and Low Range of Stoke Therapeutics?
What percentage is Stoke Therapeutics down from its 52-Week High?
What percentage is Stoke Therapeutics up from its 52-Week Low?
Current Price
$9.98
$0.72
(7.78%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.